title: Cotrimoxazole treats fluoroquinolone-resistant Salmonella typhi H58 infection.
abstract: A woman aged 20 years presented with fever and no localising signs. She was treated with cotrimoxazole and the subsequent blood culture was positive for Salmonella typhi (S. typhi), which was resistant to fluoroquinolones but susceptible to cotrimoxazole. Genotyping identified an FQ-R subclade of H58 S. typhi Fever clearance time was 4 days after starting the antibiotics, and no relapses were noted on 2 months of follow-up. This inexpensive, well-known and easily available antimicrobial could be suitably redeployed for fluoroquinolone-resistant enteric fever in South Asia.
authors: Oxford University Clinical Research Unit, Patan Hospital, Kathmandu, Nepal.
authors: Manan
authors: M
authors: Karki
authors: Oxford University Clinical Research Unit, Patan Hospital, Kathmandu, Nepal.
authors: Sarbagya
authors: S
authors: Pandit
authors: Oxford University Clinical Research Unit, Ho Chi Minh City, Vietnam.
authors: Stephen
authors: S
authors: Baker
authors: Oxford University Clinical Research Unit, Patan Hospital, Kathmandu, Nepal.
authors: Buddha
authors: B
authors: Basnyat
mesh_terms: D000900:Anti-Bacterial Agents / Q000627:therapeutic use*; D024901:Drug Resistance, Multiple, Bacterial; D005260:Female; D024841:Fluoroquinolones / Q000494:pharmacology; D006801:Humans; D008826:Microbial Sensitivity Tests; D012485:Salmonella typhi / Q000187:drug effects; D015662:Trimethoprim, Sulfamethoxazole Drug Combination / Q000627:therapeutic use*; D014435:Typhoid Fever / Q000188:drug therapy*; D055815:Young Adult
chemical_list: D000900:Anti-Bacterial Agents; D024841:Fluoroquinolones; D015662:Trimethoprim, Sulfamethoxazole Drug Combination